CJ-2360

CAT: 0804-HY-131909Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-131909Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated[1].
CAS Number
[2226742-61-4]
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK)
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cj-2360.html
Solubility
10 mM in DMSO
Smiles
N#CC1=CC(N2)=C(C3=C2N(C(C)C)C4=C(C=C(OC)C(N5C[C@H](C)N(C)[C@H](C)C5)=C4F)C3=O)C=C1
Molecular Formula
C27H30FN5O2
Molecular Weight
475.56
References & Citations
[1]Chen J, et al. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. J Med Chem. 2020;63 (22) :13994-14016.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported